SCYNEXIS, Inc. (SCYX)
NASDAQ: SCYX · Real-Time Price · USD
1.240
-0.070 (-5.34%)
Jan 8, 2025, 12:14 PM EST - Market open
SCYNEXIS Employees
SCYNEXIS had 29 employees as of December 31, 2023. The number of employees decreased by 7 or -19.44% compared to the previous year.
Employees
29
Change (1Y)
-7
Growth (1Y)
-19.44%
Revenue / Employee
$295,379
Profits / Employee
-$1,256,586
Market Cap
47.06M
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 440,000 |
Johnson & Johnson | 131,900 |
Thermo Fisher Scientific | 122,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 89,900 |
Novartis AG | 76,057 |
Merck & Co. | 72,000 |
Novo Nordisk | 64,319 |
SCYX News
- 2 months ago - SCYNEXIS Reports Third Quarter 2024 Financial Results and Provides Corporate Update - GlobeNewsWire
- 3 months ago - SCYNEXIS to Participate in the 2024 Maxim Healthcare Virtual Summit - GlobeNewsWire
- 3 months ago - SCYNEXIS to Present Preclinical Data on Second Generation Fungerp SCY-247 at IDWeek 2024 - GlobeNewsWire
- 4 months ago - SCYNEXIS to Participate in H. C. Wainwright 26th Annual Global Investment Conference - GlobeNewsWire
- 5 months ago - SCYNEXIS Reports Second Quarter 2024 Financial Results and Provides Corporate Update - GlobeNewsWire
- 6 months ago - SCYNEXIS to Receive $10 Million Milestone Payment from GSK Triggered by Delivery of Completed FURI, CARES and NATURE Clinical Study Reports - GlobeNewsWire
- 8 months ago - SCYNEXIS Reports First Quarter 2024 Financial Results and Provides Corporate Update - GlobeNewsWire
- 9 months ago - SCYNEXIS Presented Preclinical Data on Second Generation Fungerp SCY-247 at the Congress of the European Society of Clinical Microbiology and Infectious Diseases (ESCMID Global, Formerly ECCMID) - GlobeNewsWire